Relative abundances of sub-iron to iron nuclei in low energy (50-250 MeV/N) cosmic rays as observed in the Skylab experiment

A Lexan polycarbonate detector exposed on the exterior of Skylab-3 for 73 days during a solar quiet period was used to study the relative abundances of calcium to nickel ions in low energy cosmic rays of 50 to 250 MeV/N. The method of charge identification is based on the measurement of conelength (L) and residual range (R) of these particles in various Lexan sheets. Since more than one cone (sometimes as many as five) is observed and is measured, the charge accuracy becomes precise and accurate. The ratio of (calcium to manganese) to (iron and cobalt) obtained at three energy intervals of 50 to 80, 80 to 150, 150 to 250 and 50 to 250 MeV/N are 7.6 plus or minus 3.8, 2.7 plus or minus 0.8, 1.4 plus or minus 0.6 and 3.3 plus or minus 0.7 respectively. These data thus indicate a large increase of this ratio with decreasing energy. The origin of this strong energy dependence is not understood at present

Detector calibration of the Indian cosmic ray experiment (IONS) in Space-Shuttle Spacelab-13

In the Indian cosmic ray experiment (IONS) in Spacelab-3 the intention is to study nuclei up to iron in low energy cosmic rays, using CR-39 (DOP) detectors. CR-39 (DOP) was exposed to He4, C12, O16, Ne20, Si28, Ar40, Cr52 and Fe56 accelerated beams from various accelerator facilities available around the world. Different beam energies and exposure angles were used. From these exposures, the charge resolution and energy resolution for the detector in the region of interest were studied. The effect of pre-annealing and depth on the response of our detector was studied. For isotopic resolution, exposed the detector samples were exposed to Ne2O and Ne22 accelerated beams. Samples of CR-39 (DOP) exposed to different accelerated heavy ions were kept in the detector module to take into account the effect of ambient conditions on detector response during the flight

Abundance of low energy (50-150 MeV) antiprotons in cosmic rays

The progress is presented of the nuclear emulsion experiment to determine abundance of low energy antiprotons in cosmic rays. No antiprotons have been detected so far at upper limit of p/p less than or similar to 4 x .0001 in the energy range 50 MeV to 15 MeV

IONS (ANURADHA): Ionization states of low energy cosmic rays

IONS (ANURADHA), the experimental payload designed specifically to determine the ionization states, flux, composition, energy spectra and arrival directions of low energy (10 to 100 MeV/amu) anomalous cosmic ray ions of helium to iron in near-Earth space, had a highly successful flight and operation Spacelab-3 mission. The experiment combines the accuracy of a highly sensitive CR-39 nuclear track detector with active components included in the payload to achieve the experimental objectives. Post-flight analysis of detector calibration pieces placed within the payload indicated no measurable changes in detector response due to its exposure in spacelab environment. Nuclear tracks produced by alpha-particles, oxygen group and Fe ions in low energy anomalous cosmic rays were identified. It is calculated that the main detector has recorded high quality events of about 10,000 alpha-particles and similar number of oxygen group and heavier ions of low energy cosmic rays

Observations of enhanced sub-iron (Sc-Cr) to iron abundance ratios in the low energy galactic cosmic rays in Spacelab-3 and their implications

The Anuradha cosmic ray experiment in Spacelab-3, flown in the orbit at 350 km with an inclination of 57° for about six days, was used to measure the low energy galactic cosmic ray (GCR) heavy ions using a specially designed CR-39 detector module incorporating the arrival time information of the particles. The abundances of sub-iron (Sc-Cr) and iron particles in the low energy interval of 30-300 MeV/N were determined from the measurements made in four different depths of the CR-39 detector module of 150 layers. From these studies we obtained sub-iron (Sc-Cr) to iron abundance ratios of 0.8 to 1.2 in 30-300 MeV/N energy range. It is found that these ratios are enhanced by a factor of two as compared to interplanetary ratios of about 0.5. It is shown that the enhancement of the ratio inside the earth's magnetosphere is probably due to the degree of ionization of low energy Sc to Cr and Fe ions in the galactic cosmic rays and to the rigidity filtering effects of the geomagnetic field. Further studies are needed to understand fully the phenomena and their implications

Anomalous Cosmic Rays and their Ionization States

Ionization states of 16 individual anomalous cosmic ray events have been determined in the anuradha cosmic ray experiment conducted onboard Spacelab-3. The geomagnetic field was used as a rigidity filter for the energetic charged particles, and the upper limit on their ionization states is obtained by using the relation Z <= M.p.c/R/sub c/. Out of 16 events, 11 are found to be singly ionized and the other five events are consistent with their being in singly ionized states. The singly ionized nature of the anomalous cosmic ray particles suggests neutrals in the local interstellar space as their source

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362